UPDATE: BMO Capital Downgrades Akcea Therapeutics, Inc. (AKCA) to Market Perform
Get Alerts AKCA Hot Sheet
Rating Summary:
1 Buy, 4 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 16 | Down: 11 | New: 13
Join SI Premium – FREE
(updating comment)
BMO Capital analyst Do Kim downgraded Akcea Therapeutics, Inc. (NASDAQ: AKCA) from Outperform to Market Perform with a price target of $18.15 (from $26.00).
THe analyst comments "Ionis/Akcea announced that Ionis will acquire the remaining 24% of Akcea's shares outstanding ($18.15/share) in a $500mn merger transaction ($2B valuation). We believe the acquisition makes strategic sense, leveraging Akcea's existing relationships and commercial infrastructure, as Ionis expands its wholly owned pipeline. We believe Akcea as the commercial arm will drive long-term growth, as Ionis develops assets further into late-stage development and commercialization, creating more value for retained assets. We lower our target price to $18.15 from $26 and downgrade AKCA shares to Market Perform from Outperform, as we expect the acquisition to complete with no competing bidders."
For an analyst ratings summary and ratings history on Akcea Therapeutics, Inc. click here. For more ratings news on Akcea Therapeutics, Inc. click here.
Shares of Akcea Therapeutics, Inc. closed at $11.38 yesterday.
You May Also Be Interested In
- Wolfe Research Downgrades Warner Brothers Discovery (WBD) to Underperform, 'out of concern that an incipient advertising downturn put guidance at risk'
- Citi Downgrades UBS AG (UBSG:SW) (UBS) to Neutral
- Ellington Credit Company (EARN) Adopts Tax Asset Preservation Plan
Create E-mail Alert Related Categories
Analyst Comments, Analyst PT Change, DowngradesRelated Entities
BMO Capital, Definitive AgreementSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!